Intragastric administration of the bitter tastant, quinine, reduces postprandial plasma glucose without affecting gastric emptying in health
Year: 2026
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Abstract: PURPOSE: In health and type 2 diabetes, intraluminal administration of quinine stimulates glucoregulatory hormones and slows gastric emptying, key determinants of postprandial plasma glucose, following oral carbohydrate. We have now investigated these effects following a mixed solid-liquid meal, with gastric emptying quantified using scintigraphy, the 'gold-standard' technique. METHODS: Ga-EDTA), in randomised, double-blind fashion. Plasma glucose, insulin and glucagon were measured at baseline, for 60 min before, and for 120 min after, the meal. Gastric emptying was measured using scintigraphy. Data were analysed using repeated-measures ANOVA. RESULTS: Q600 and Q300 both reduced plasma glucose immediately before the meal, at t=-5 min, as well as overall and peak postprandial glucose, when compared with control, in a dose-dependent manner (P < 0.05). Q600 stimulated plasma insulin before the meal at t=-20 min (P = 0.04), and the postprandial plasma insulin-to-glucose ratio (P = 0.02), compared with control. Both overall and peak postprandial plasma glucose were inversely related to plasma insulin at t=-20 min (R<-0.51, P < 0.05). Quinine did not affect plasma glucagon or gastric emptying. CONCLUSION: Intragastric quinine lowers the plasma glucose response to a mixed solid-liquid meal in middle-aged individuals without diabetes by stimulating preprandial insulin, without affecting either plasma glucagon or gastric emptying. TRIAL REGISTRATION: The study was registered as a clinical trial with the Australian and New Zealand Clinical Trials Registry ( https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=383933&isReview=true ; ACTRN12622000735752, date of registration: May 23, 2022).
Source: European Journal of Nutrition
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $2,890
OpenAlex ID: W7236475080
